semaglutide essence ESSENCE: in Patients with Metabolic Dysfunction–Associated Steatohepatitis Semaglutide in metabolic dysfunction-associated steatohepatitis.

Access to advanced therapies, established treatment protocols, and patient awareness further support adoption

A Monell Chemical Senses Center study published this week in the Journal of Clinical Investigation offers renewed hope for individuals living with Bardet-Biedl Syndrome (BBS), a rare genetic disorder characterized by early-onset obesity, compulsive eating, and cognitive impairments

Yamada Y, Katagiri H, Hamamoto Y, et al

References are provided solely for scientific and educational discussion

At 208 weeks, semaglutide was associated with mean reduction in weight (10.2%), waist circumference (7.7 cm) and waist-to-height ratio (6.9%) versus placebo (1.5%, 1.3 cm and 1.0%, respectively

With its patent expiration, the advent of generic Semaglutide offers new possibilities, opening up a more affordable avenue for millions